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Abstract
Metastasis from breast cancer leads to a higher chance of death from that cancer.
According to the National Cancer Institute (2018) breast cancer survival rates among all
three SEER stages (localized, regional, and distant) was approximately 90% between the
years 2008 and 2014. Among these patients, those with distant metastasis had a survival
rate of 27% and those with regional metastasis had an 85% survival rate (American
Cancer Society, 2019). When creating an individualized anesthetic plan for a patient
presenting for tumor excision of breast cancer, the anesthesia provider should create a
plan that lowers the risk of metastasis and increases the patient’s chance of survival. The
purpose of this systematic review was to analyze which anesthetic technique, Propofol
based total Intravenous Anesthesia (TIVA) or Sevoflurane based inhalation anesthetic,
will elicit less immune response. A comprehensive literature review was completed using
CINAHL, Medline Plus, and Pubmed Health focusing on propofol based TIVA and
Sevoflurane for anesthesia maintenance for the removal of cancerous breast tumors. The
PRISMA model was used to identify eligible studies. Study analysis was completed by
creating study specific and data outcome tables. Critical appraisal of individual
randomized control trials was performed using the Critical Appraisal Skills Programme
(CASP) checklist. A cross study analysis table was also created to compare the results of
all eligible studies. The findings of this systematic review determined that Propofol based
TIVA increases recurrence free survival, however there is negligible differences in the
immune response between Propofol based TIVA and Sevoflurane inhalation anesthetic
for women undergoing surgery for breast cancer tumor excision.
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Propofol Based TIVA Vs. Sevoflurane Inhalation Anesthetic for Breast Cancer Surgery: A 1
Systematic Review
Background/Statement of the Problem
Treatment of choice for many solid tumor cancers is excision of the tumor via
surgery (Anand et al. 2015). Anesthesia plays an important role in the success, comfort,
and overall surgical experience for the patient. The anesthesia provider should form an
anesthetic plan that factors in the physiologic and pathophysiologic conditions of the
specific patient (Nagelhout & Plaus, 2016). There is much debate about which type of
anesthesia is best for patients undergoing surgery for the excision of cancerous tumors.
Some studies have shown that Propofol and local anesthetics are the best choice to limit
cancer metastasis Ito et al. (2017). However, many providers still choose to use a general
anesthetic technique that includes the use of volatile agents such as Sevoflurane.
According to the National Cancer Institute (2018) breast cancer survival rates
among all three SEER stages (localized, regional, and distant) is approximately 90%
between the years 2008 and 2014. Among these patients, those with distant metastasis
had a survival rate of 27% and those with regional metastasis had an 85% survival rate.
This shows that the more metastasis to distant areas, the lower the chance of survival of
the patient (American Cancer Society, 2019). When creating an individualized anesthetic
plan for a patient presenting for tumor excision of breast cancer, the anesthesia provider
should create a plan that lowers the risk of metastasis and increases the patient’s chance
of survival. It is hypothesized that Total Intravenous Anesthesia (TIVA) for the
maintenance phase of anesthesia during surgical excision of cancerous tumors of the

breast will limit the number of immune cells released that are related to cancer
metastasis.
The purpose of this study is to examine if Total Intravenous Anesthesia versus
Sevoflurane is more efficacious in limiting the amounts of immune cells released during
the perioperative period in breast cancer patients.
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Literature Review

3

The literature presented here will provide general background on immunity,
immune system changes that lead to cancer metastasis, breast cancer, surgeries to excise
breast cancer, the impact these procedures have on the immune system, and anesthetic
choice for breast cancer surgery. Immunemodulation from anesthetic choice will also be
explored. Data was searched from 2002-present for this review. Search databases include
CINAHL, Medline Plus, and Pubmed Health. Additional data was sought in textbooks
and Google scholar with relevance to the topic.
Keywords: anesthesia, breast cancer, breast cancer surgery, immune response,
immunosuppression, propofol, sevoflurane, TIVA, general anesthesia, volatile
anesthetics, and survival rates.
The aim of this project is to examine if Total Intravenous Anesthesia versus
Sevoflurane is more efficacious in limiting the amounts of immune cells released during
the perioperative period in breast cancer patients. This topic is relevant and valuable to
the discussion on anesthetic choice and its impact on immune system and overall survival
of breast cancer patients. Surgery evokes a surgical stress response and with it an immune
response in all patients. Anesthetics also impact the immune system. Given these
contributory factors, it is important to select an anesthetic that will provide less
immunocompromise to at risk populations including breast cancer patients.
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Immunity
The human body is able to resist infection from organisms as well as recognize
aberrant cell growth, through the immune system. Immunity falls into two classifications
with some overlapping cells and processes.
The first type of immunity is innate immunity (Guyton & Hall, 2011). Innate
immunity has several functions. Innate immunity phacocytizes bacteria via macrophages
and white blood cells, destroys organisms though the acid that is secreted in the stomach,
resists invasion or organisms through the epithelial layer, and the utilization of chemical
compounds that attach to foreign organisms and or toxins (Guyton & Hall, 2011). Cells
that play a role in innate immunity include epithelial cells, monocytes, macrophages,
dendritic cells, natural killer cells (NK), and leucocytes. Various lymphocyte subtypes
help bridge innate and acquired immunity. These subtypes include CD5-positive Blymphocytes and gd T-lymphocytes (Guyton & Hall, 2011).
The second type of immunity is acquired immunity. The cells involved in this
branch of immunity are lymphocytes. This includes B-lymphocytes, T-lymphocytes, and
natural killer cells (NK) (Eissmann, 2015). Acquired immunity works by creating genetic
mutations on the B and T lymphocytes. These are expressed as antibodies and T cell
receptors. When antibodies or T-cell receptors bind to antigens proliferation of antigenspecific lymphocytes occurs. A specific immune response then ensues. Each antibody
binds to specific antigens. This specificity allows for selective proliferation of clonal
lymphocytes that correlate with the antigen (Guyton & Hall, 2011).

Other key elements include major histocompatibility complex (MHC) and
cytokines. These allow for cell-to-cell communication that is involved in both acquired
and innate immunity. Another component in acquired immunity is the surface protein
CD40. When combined with its receptor a costimulatory signal for interaction between
antigen presenting cells and T-cells (Adam et al., 2003). Between innate and acquired
immunity there is overlap. Both types of immunity interact, and in some cases utilize cell
types to carry out the overall function of the immune system.
The Immune System’s Role in Neoplasia and Metastasis Development
Cancer develops from the body’s normal cells and transitions into cancer cells
through deranged growth. There are seven common characteristics of the transition from
normal cells to cancerous cells. This includes the ability of cancer cells to stimulate their
own growth, resist the immune systems efforts to halt growth, cancer cells are not subject
to normal apoptosis, they are able signal for new blood vessel development through
angiogenesis, they multiply indefinitely, metastasize to other sites, and invade both
acquired and innate immune system (Malik et al. 2014).
Once cancer cells have developed, they are able to form a primary tumor site
known as a neoplasia. As the neoplasia develops its genetic makeup is changed to further
aid in the development of more cancer cells and metastasis. With ongoing tumor growth,
a normal inflammatory response is invoked, which signal for neutrophils, eosinophils,
and monocytes to come to the tumor site. This creates an environment that is favorable
for metastasis (Malik et al. 2014).
Research shows that there is a link between immune system dysfunction and the
development of cancer metastasis. As pointed out by Critchley-Thorne et al. (2009),
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innate immune dysfunction is a common defect in cancer patients. Specifically, the
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interferon signaling pathway is impaired, which, leads to lymphocyte dysfunction in
cancer patients. To demonstrate this, Critchley-Thorne et al. (2009), took peripheral
blood samples from patients who had breast cancer, gastrointestinal cancer, or melanoma.
They then analyzed the samples from these patients and looked at the amount of
interferon signaling gene expression (ISG) (Critchley-Thorne et al., 2009). The
researchers found that the levels of the five major ISGs, were decreased when compared
to healthy controls: STAT1, p = 0.0381; IFI44, p = 0.0303; IFIT, p = 0.0480; IFIT2, p =
0.0177; and MX1, p = 0.019 (Critchley-Thorne et al., 2009). This is indicative of
lymphocyte dysfunction, which, leads to a decreased immune response in cancer patients.
This decreased response allows for immune suppression and places the patient at a higher
risk for infection. Chrichley-Thorne et al. (2009) also measured the response to IFN-a
and IFN-g stimulation in the peripheral blood lymphocyte samples from twenty-seven
breast cancer patients (Critchley-Thorne et al., 2009). These patients had breast cancer
stage two, three, and four. The researchers did the same for twelve patients with
melanoma in stage three and four, as well as eleven patients with gastrointestinal cancer
staged two, three, and four. These results were compared to twenty-eight aged matched
healthy controls (Critchley-Thorne et al. 2009). The researchers found that changes in
pSTAT1 induced by IFN-a was significantly reduced in T, B, and NK cells within all of
the cancer types versus health controls (p < 0.05) (Critchley-Thorne et al., 2009). STAT1
plays a vital role in the formation of proteins necessary for the immune system to
recognize and destroy viruses via the interferon alpha/beta pathway (US National Library
of Medicine, 2019). The researchers then extrapolated that IFN signaling is reduced in

early stages of cancer and remains reduced in later stages (Critchley-Thorne et al., 2009). 7
Thus, leaving cancer patients vulnerable to viral infections. Further research suggested by
Critchley-Thorne et al. (2009), at the conclusion of this study, included enhancement of
the human immune systems as a way to resist existing neoplasia and negate metastasis.
Since the work of researchers like Critchley-Thorne et al. (2009), immunotherapy
has become a broad and ever-growing field. There are several types of immunotherapy
treatments being developed as treatments for breast cancer. Vaccination as a way to get
the immune system to recognize and attack cancer cells is one such example. For
example, Delirezh, et al. (2016) sought to develop a vaccine to allow the immune system
to recognize and thus attack the breast cancer cells. These researchers injected 4T1
mammary carcinoma cells into mice and waited until a palpable tumor developed. Mice
were then randomly placed into either a control group where they received vaccines of
phosphate buffered saline and a vaccination group, a vaccination group with 4T1 (4T1)
only, or a vaccination group with 4T1 and naloxone (4T1+NLX). Naloxone has been
used in cancer studies as an adjuvant to solutions and vaccinations (Bimonte et al., 2018).
Naloxone has been shown to decrease the proliferation of breast cancer cells of the
estrogen receptor-negative human breast carcinoma cells strain (Bimonte et al., 2018).
Furthermore, Naloxone has also been shown to induce cancer cell apoptosis (Bimonte et
al., 2018).
The vaccination groups were injected at regular intervals with heated 4T1 extract
mixed with naloxone (Delirezh, et al., 2016), and a second ground that received 4T1
without any additive. Tumor growth was measured throughout the injection period. The
amount of splenocyte and cytokine release was measured after euthanasia. Splenocytes

are white blood cells that come from the spleen. The reduction in splenocytes are
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indicative of a suppressed immune system (Guyton & Hall, 2011). Cytokines are peptides
that are secreted by cells and function as signaling molecules. Examples of cytokines
include interleukins and lymphokines (Guyton & Hall, 2011). The reduction in cytokines
leads to less signaling and overall reduction in function of both innate and acquired
immunity (Guyton & Hall, 2011).
Cytokine release IFN-g production was upregulated in the heated 4T1+NLX
group as compared to the control group (p<0.05) (Delirezh, et al., 2016). Overall tumor
size was also decreased in the 4T1+NLX group (p <0.05). There was also more
phagocyte production in the 4T1+NLX group when compared to the control group
(p<0.001). Tumor size in the 4T1 group was similar in size to the control tumor mice.
Splenocyte proliferation was higher in the 4T1+NLX group compared to the 4T1 mice.
Overall findings indicate that vaccination utilizing heated 4T1 with naloxone increases
the ability of the immune system to recognize breast cancer cells, increases the amount of
phagocytes available to destroy the cancer cells, and limits overall tumor growth
(Delirezh, et al., 2016).
Breast Cancer
According to the United States Center for Disease Control and Prevention, breast
cancer is the most common type of cancer among women of all races (Centers for
Disease Control, 2019). In the year 2016, there were 245,299 new cases of breast cancer
in the United States (Centers for Disease Control, 2019). Forty-one thousand, four
hundred eighty-seven women died of breast cancer in 2016. The risk of getting breast
cancer among women of all races has not increased overall in the last decade (Centers for

Disease Control, 2019); However, it has increased significantly among African
Americans and Asian Americans races. Risk factors for breast cancer are both modifiable
and nonmodifiable. Modifiable risk factors that increase the risk of breast cancer include
sedentary lifestyle, obesity, hormone replacement post-menopause and hormone birth
control (Aryandono et al., 2017), reproductive history including not having a child or
having a child over the age of 30, and alcohol intake (Centers for Disease Control, 2019)
. Nonmodifiable risk factors include increased age, genetic mutations such as having the
BRCA1 or BRCA2 gene, having dense breasts, family history of breast cancer
(Aryandono et al., 2 017), and previous radiation therapy (Centers for Disease Control,
2019).
Early detection of breast cancer increases overall survival and usually discovered
via mammography; however the lesion may be found by an individual during a breast
self-exam (Norris, 2019). Diagnosis of breast cancer is done through mammography,
ultrasonography, needle aspiration, and or excisional biopsy. Breast cancer often presents
as a unilateral, solitary, firm, fixed, painless lesion. Usually the boarders are poorly
defined (Norris, 2019).
Surgical resection of tumors is considered a definitive and first line treatment for
solid neoplasms such as breast cancer (Ben-Eliyahu & Neeman, 2013). However,
surgery is often associated with promotion of micrometastasis, which then allow for the
development of new metastatic sites (Ben-Eliyahu & Neeman, 2013). According to the
National Cancer Institute (2019), micrometastasis are small numbers of cancer cells that
are released and spread away from the primary tumor site; however, the amount is too
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small to be detected on any screening or diagnostic test. If left unchecked by the immune10
system, micrometastasis leads to additional tumor sites throughout the body.
Recenlty, Chang et al. (2019) identified a key enzyme involved with inhibition of
the immune system in response to breast cancer. Specifically, the immune system’s
ability to upregulate the amount of CD8+ T cells available, as well as the amount of
immune stimulatory myeloid subsets (Chang et al., 2019). Certain types of breast cancers
can upregulate the enzyme calcium/calmodulin-dependent kinase (CaMKK2), which
allows for the suppression of CD8+ and immune stimulatory myeloid subsets. Once
CD8+ and immune stimulatory subsets are inhibited, neoplasia can successfully avoid
recognition, and ultimately destruction, by the immune system (Chang et al., 2019).
Researchers took breast cancer samples from willing participants and extracted cells.
Cells were then injected into murine models and samples of the tumors were collected
(Changet al., 2019). Results revealed that CaMKK2 was present at high levels within the
breast cancer cells, and CD8+ T cells were suppressed (p <0.05). However, when the
researchers suppressed CaMKK2 in breast cancer cells, CD8+ T cells were then
detectable, and resulted in tumor growth inhibition (p <0.05) (Chang et al., 2019). This
study demonstrates that by inhibiting the CaMKK2 pathway, CD8+ cells are available to
aid in tumor suppression and limit overall tumor cell growth.
Surgical Procedures for Excision of Cancerous Breast Tumors.
Historically, radical mastectomies were the surgery of choice for breast cancer.
This surgical technique is very invasive and involves the removal of the breast and
underlying pectoral muscles. During this procedure the axillary lymph nodes are also

removed. This technique has been replaced with less invasive techniques (Golianu et al.,11
2018).
There are now two primary, minimally invasive, approaches to excision of
cancerous breast tumors. One technique spares most breast tissue. The aim of this
approach is to remove the tumor only. This approach is termed lumpectomy. The second
approach is removal of the breast in its entirety. This is called mastectomy (Dave et al.,
2010). Mastectomy is the technique of choice for more invasive breast cancer with
extensive duct involvement or with a perceived high risk of metastasis. Mastectomy can
also be done prophylactically for high risk patients. Both techniques can be accompanied
by lymphatic mapping, sentinel node biopsy, and or axillary dissection (Golianu et al.,
2018).
In a twenty year follow up to a randomized control trial, investigators found no
difference in survival rates between radical mastectomy and less invasive surgical
techniques (Cascinelli et al., 2002). From the years 1973 to 1980, 701 women with breast
cancer tumors that measured more than 2 cm were randomly assigned to undergo either a
radical mastectomy or less invasive quadrantectomy (Cascinelli et al., 2002). Both groups
received radiotherapy to the ipsilateral breast tissue. There were 349 patients in the
radical mastectomy group and 352 in the quadrantectomy group. After the year 1976 if
patients in either group had positive axillary node involvement, they then received
chemotherapy (Cascinelli et al., 2002). At the twenty year follow up, thirty women in the
quadrantectomy group had tumor recurrence in the same breast while eight women had
local recurrences in the radical mastectomy group, which is a statistically significant
difference (p < 0.001) (Cascinelli et al., 2002). There was no significant difference

between the two groups in the rates of contralateral breast cancers, distant metastases, or12
secondary cancers.
At the 20 year follow up the rate of death from all causes was found to be 41.7
percent in the quadrantectomy group and 41.2 in the radical mastectomy group
(Cascinelli et al., 2002). During that same time period, it was shown that there was more
cancer recurrence and associated metastasis with less invasive techniques, such as
lumpectomy. This is linked with the amount of micrometastasis at time of diagnosis and
not with the surgical technique (Cascinelli et al., 2002). Overall surgery no matter what
type, is associated with the acceleration and development of micrometastasis and the
promotion of new metastasis.
The processes thought to be responsible for metastasis related to surgery is the
suppression of acquired immune cell responses. Surgery involves the manipulation of the
neoplasm, its surrounding vasculature, and lymphatic system (Ben-Eliyahu &
Goldfarb,2007). During the perioperative period, natural killer cell suppression and
upregulation of proangiogenic factors such as VEGF, allow for micrometastasis to not
only evade recognition, and stop the metastatic cells from being phagocytized, but allow
for easy invasion to other areas (Ben-Eliyahu & Goldfarb, 2007). Although the
pathophysiology behind natural killer cell activity suppression after surgery is still not
completely understood, it has been shown to be suppressed within hours of the surgery,
and has been shown to last for several days postoperatively (Ben-Eliyahu & Goldfarb,
2007). There are several proposed mechanisms that could explain the decrease in NK cell
cytotoxicity post-surgery. According to Lotzva et al. (1991), NK cell cytotoxic
impairment is caused by a “toxic” effect. This is caused by the surge of catecholamines,

glucocorticoids, and prostaglandins from surgery. Together these substances have been 13
shown to suppress NK cell activity (Lotzva et al., 1991). A study by Angka et al. (2017),
linked the inflammatory response, specifically the increased amount of IL-6 production
during both the acute proinflammatory phase and the prolonged anti-inflammatory phase,
with NK cell suppression and cytotoxicity.
The deleterious effects associated with surgery are mediated through several
mechanisms. This includes the surgical stress response that is mediated by
neuroendocrine and metabolic responses (Buggy et al., 2006). These responses lead to a
transient inhibition of the immune system, which allows for the cancer cells to further
metastasize and develop new tumor sites (Buggy et al., 2006).
Anesthesia Plans for Breast Cancer Tumor Excision
Anesthetic plans are determined on an individual basis and are decided upon due
to the patient’s pathophysiologic conditions, physical limitations, adverse medication
reactions, and creating optimal surgical conditions. However, some generalizations can
be made. In the case of breast cancer tumor excision, the decision to use one technique
over the other is based on many factors including anesthetic provider preference, surgeon
preference, the patients’ physiologic state, and type of procedure being performed
(Nagelhout & Plaus, 2016). General anesthesia is always used, although the type of
general anesthetic may vary. Sometimes providers may utilize regional techniques, such
as paravertebral blocks, to provide more postoperative pain relief (Golianu et al., 2018).
General anesthesia: Volatile agent Sevoflurane. General anesthesia consists of
insertion of an advanced airway, such as laryngeal mask airway or endotracheal tube
(Nagelhout & Plaus, 2016). his allows the provider to ventilate the patient and administer
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volatile anesthetic agents (Nagelhout & Plaus, 2016). Volatile agents allow for the patient
to be placed in stage three of general anesthesia (Nagelhout & Plaus, 2016). In this stage
patients will not respond to noxious stimuli such as a surgical incision (Nagelhout &
Plaus, 2016). There are several volatile agents used in practice today to achieve this depth
of anesthesia. One of the most commonly used agents is Sevoflurane (Nagelhout & Plaus,
2016).
Sevoflurane is a newer inhaled anesthetic that was discovered in the late 1960s
and began to be commonly used in the 1990s. Advantages of sevoflurane include rapid
uptake and elimination. It has good bronchodilating properties that make it appropriate
for use in asthmatics and to lessen the risk of bronchospasm during induction,
maintenance, and emergence phases of anesthesia. The cardiovascular effects are similar
to that of an older volatile agent isoflurane. It provides good heart rate stability with
slight reductions in cardiac output. Like all volatile agents, it provides dose dependent
reductions in systemic vascular resistance and mean arteriolar pressures (Nagelhout &
Plaus, 2016).
There are some disadvantages specific to sevoflurane. It is highly reactive with
the desiccated carbon dioxide absorbent soda lime. When used with desiccated
absorbents, sevoflurane has been linked with machine fires and patient injury. A second
disadvantage is that it has been shown to cause renal failure in murine studies. This was
attributed to Compound A formation when sevoflurane was administered with fresh gas
flow rates less than two liters per minute (Nagelhout & Plaus, 2016).
All volatile anesthetic agents suppress all components of the immune system. This
includes acquired and innate immune system components. The amount and which

specific cells are suppressed, depend on the agent used (Benzonana et al., 2011).
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Specifically, Sevoflurane has been shown to decrease the number of neutrophils,
macrophages, T lymphocytes, and B lymphocytes (Dou et al., 2016). Sevoflurane has
also been shown to reduce the cytotoxicity of NK cells (Dou et al., 2016).
A study done by Buggy et al. (2013), which utilized in vitro models, demonstrated
increased breast cancer proliferation and metastasis with the use of Sevoflurane. Two
types of breast cancer cells were utilized for this study, MCF7 ER+, which is estrogen
receptor negative human breast adenocarcinoma, and MDA-MB-231 ER-, estrogen and
progesterone receptor-positive human breast adenocarcinoma (Buggy et al., 2013). Both
types of cells were incubated with or without Sevoflurane at concentrations of 1, 2, 3, and
4 mM for six hours. The researchers utilized cell proliferation migration and invasion
assays to measure the effects of the Sevoflurane on the breast cancer cells. An
independent t-test analysis compared for differences between the Sevoflurane and nonSevoflurane groups. Sevoflurane increased proliferation of MCF7 cells by 50-60%
(Buggy et al., 2013). Sevoflurane was also found to increase proliferation of MDA-MB231 cells by 50-67% (p<0.05) (Buggy et al., 2013). Sevoflurane increased migration by
30-58% in the MCF7 (p = 0.04) and 30-230% in the MDA-MB-231 group (Buggy et al.,
2013). Invasion ranged from 100-170% in MCF-7 (p = 0.02) and 28-72% in the MDAMB-231 group, with statistical significance at the 4 mM concentration (Buggy et al.,
2013). This study demonstrates that Sevoflurane inhalation anesthetic creates a
proliferation of breast cancer cells, thus is not the ideal choice for breast cancer surgery.
Total intravenous anesthesia. Total Intravenous Anesthesia (TIVA) is the
maintenance of anesthesia using intravenous medications only. No inhalation agents are

used for the maintenance phase of the anesthetic. The most common indication for TIVA16
is if the patient has a known history of malignant hyperthermia or has a risk for malignant
hyperthermia. Some less common indications include long QT syndrome, surgery
requiring neurophysiological monitoring, and Myesthenia Gravis and other neurological
disorders to avoid neuromuscular blocking agents (Al-Rifai & Mulvey, 2016).
Commonly propofol is used as the agent of choice for TIVA. It provides good hypnosis,
amnesia, and has some level of antiemetic effect. Propofol can also be used in
conjunction with the opioid Remifentanil to provide adequate pain management and
synergistic sedation for the maintenance phase of the anesthetic (Nagelhout & Plaus,
2018). Propofol does not impair the function of NK cells like Sevoflurane does (Dilger,
2018). Propofol has also been shown to have better long-term survival rates when
compared to volatile agents such as Sevoflurane (Jhanji et al., 2016).
In addition to the above listed benefits, propofol has been shown to aid in the
infiltration of cancerous tumors with the body’s own NK cells and T lymphocytes
(Buggy et al., 2015). In a follow-up pilot study done by Buggy et al., (2015), ethics
committee approval was given to contact patients currently involved in another breast
cancer study. Thirty women who were already randomized into another clinical trial were
contacted and consented to have their breast tissue reviewed and re-stained for
immunocyte infiltration. Participants were randomized into two anesthetic groups:
Propofol-paravertebral anesthesia (PPA, n=12) or general anesthesia with opioid
analgesia (GA, n=16) (Buggy et al., 2015). The amount of infiltration was measured via
the amount of CD4 (T Helper cells), CD8 (T suppressor cells), CD56 (NK cells) and
CD68 (macrophages) cells that were present in the sample after staining (Buggy et al.,

2015). The normalized positive intensity values (median and interquartile range IRQ) 17
showed that CD56 (NK cells) was lower in the GA group 121 versus the PPA group 136
(p = 0.015). The CD4 (T Helper cells) cell count was also lower in the GA group 10.9
(5.5-27.8) versus PPA 19.7 (14.4-83.5) (p = 0.03) (Buggy et al., 2015). This
demonstrated that there is more infiltration by NK cells as well as T helper cell into
breast cancer samples, as the overall number of NK cells and T helper cells present in the
stained tissue was higher. If there are more NK cells present to mount an immune
response against the cancer cells there will be less metastasis.
In murine models propofol has further been shown to suppress some NK activity
but lead to less metastasis when compared to thiopental, ketamine, and halothane (BarYosef, et al., 2003). In a study of 344 anesthetized rats, subjects were anesthetized for
one hour with either: ketamine, thiopental, halothane, or propofol (Bar-Yosef, et al.,
2003). The rats were then injected with breast cancer, specifically MADB106, tumor
cells (Bar-Yosef, et al., 2003). At the twenty-four hour mark the amount of lung
metastasis was counted. A second count of metastasis was made at the three-week mark.
The researchers also counted the amount of circulating NK cells right after anesthesia.
Propofol caused a 23.5% reduction in NK cells whereas thiopental had an NK reduction
of 55.13%, which was the largest NK reduction among the selected agents (Bar-Yosef, et
al., 2003). Ketamine demonstrated the highest amount of lung metastasis whereas
propofol had the least amount (Bar-Yosef, et al., 2003).

Sevoflurane Versus TIVA for Surgical Excision of Breast Cancer
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Several studies have examined the connection between cancer, immunity, and
metastasis. For example, according to Ah et al. (2016) propofol independently reduces
cancer cell migration and leads to less metastasis. This led researchers in this
retrospective study to examine if propofol based TIVA or sevoflurane anesthesia for
modified mastectomy would lead to better five-year survival rates. Ah et al. (2016)
analyzed data from 363 cases. Of these, 173 patients underwent modified radical
mastectomy with TIVA and 152 underwent modified radical mastectomy with
sevoflurane. The findings showed that there were no differences in survival between the
two groups. However, the TIVA group had a significantly lower cancer recurrence rate
(11.6%) versus the sevoflurane group (19.1%) (p = 0.037) (Ah et al., 2016). At the fiveyear mark, 9 of 173 (5.2%) patient deaths occurred in the Propofol group whereas 11 out
of 153 (7.2%) patients in the Sevoflurane group had passed away (Ah et al., 2016).
Andreasson et al. (2014) also demonstrated that propofol was a better anesthetic
choice for one-year survival for breast cancer patients than sevoflurane. In a retrospective
case study, researchers examined surgical cases for patients undergoing a variety of
surgical procedures for resection of cancer. Women who had undergone resection of
breast cancer tumors were included, as well as patients who had undergone procedures
for colon and rectal cancers. One thousand eight hundred and thirty-seven breast cancer
patients were included within the study population. Although investigators found no
overall difference in survival between sevoflurane or TIVA groups at the five-year mark,
there were significant findings for the one-year mark. Specifically, the findings showed
that breast cancer patients had a better survival rate at the one-year mark when TIVA had

been used versus sevoflurane (Andreasson et. al., 2014). Patients that had undergone
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breast cancer surgery with sevoflurane based anesthesia had a one-year survival
confidence interval of 0.96, whereas the propofol based TIVA group had a confidence
interval of 0.99 at the one-year mark (Andreasson et. al., 2014). The difference in
survival between the two groups was a confidence interval of 0.03 (0.01-0.04) (p < 0.001)
(Andreasson et. al., 2014). In addition, the researchers looked at all surgical survival rates
combined, and found that propofol based TIVA had a better overall survival rate (p =
0.004) (Andreasson et. al., 2014).
The immune system is complex and its influence on the development of breast
cancer and metastasis is even more so. Research has shown that when the immune system
is unable to function in its normal capacity, breast cancer is able to develop and
eventually metastasize. Several studies have shown that the type of general anesthesia
used for the maintenance phase of breast cancer tumor excision, either volatile agent
Sevoflurane or TIVA, can suppress the immune system and aid in development of
metastasis. As anesthesia providers formulate an anesthetic plan for patients undergoing
breast cancer tumor excision, immune system optimization should be a primary goal.
Selection of a general anesthetic should limit the amount of immune response, which in
turn could lead to better long-term survival.
Therefore, the purpose of this systematic review is to examine if Total
Intravenous Anesthesia versus sevoflurane is more efficacious in limiting the amounts of
immune cells released during the perioperative period in breast cancer patients. Relevant
literature was explored to examine anesthetic choice and its effect on the immune system,

surgical advances impact on survival, and breast cancer survival rates with Sevoflurane 20
and TIVA.
Next the theoretical framework used to guide this study is presented.

Theoretical Framework
A theoretical framework is utilized in research to serve as an organizational
outline that pertains to a particular theory. The theoretical framework helps to serve
insight into the topic of choice. It also provides strength to the research as well as gives
reasoning as to why a particular topic requires further study.
The theoretical framework that guided this systematic review is the Preferred
Reporting Items for a Systematic Reviews and Meta-Analyses (PRISMA). PRISMA is
a 27-item checklist and a flow diagram. The diagram is a four-phase diagram (Altman et
al., 2009). The included items are necessary for transparent reporting of a systematic
review.
The PRISMA checklist is divided into seven sections. These sections include
abstract, introduction, methods, results, discussion, and findings (Altman et al., 2009).
Each section is used to compile a thorough review of each article (Altman et al, 2009).
The four-phase diagram is a graphic representation of the final articles used. It
identifies the articles used, screening used, and eligibility determination. The diagrams,
shown on page 27 and 28, also illustrate how many records were found and which
databases were searched (Altman et al., 2009).
Next, the methods will be discussed.
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Figure 1. PRISMA Checklist
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Figure 2. PRISMA Flow Diagram

Methods
Purpose
The purpose of this study is to examine if Total Intravenous Anesthesia versus
sevoflurane is more efficacious in limiting the amounts of immune cells released during
the perioperative period in breast cancer patients.
Design
The design of this study is a systematic review of the literature.

Search Strategy
Research studies were sought through data bases including Pubmed, CINHAL,
and Medline. Search terms included were: Sevoflurane, TIVA, breast cancer surgery,
mastectomy, immune response, and lumpectomy. Additional literature was sought using
Google Scholar.
Inclusion/Exclusion Criteria
Inclusion criteria for studies reviewed were: (a) adult females age 20-80 (b)
female patients undergoing surgical procedures for the excision of breast cancer tumors
(c) randomized control trials that have compared TIVA to sevoflurane as the anesthetic
during the maintenance portion of the procedure, and (d) quantitative measurement of
amounts, as well as identification of types of cells measured. Studies that utilized
supplemental pain control or nerve blocks for pain management were included. Studies
were included regardless of induction agent used. Studies including males, children, and
females over the age of 80 years old were excluded.
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Data Collection
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The study information collected included aim, design, site, sample, method, and
outcomes. Outcome specific data sought included the inflammatory cell that
was measured and patient outcomes related to amount of metastasis. The primary
outcome variable that was collected is the amount of immune cell released in response to
the specific type of anesthesia.
Critical Appraisal and Cross Study Analysis
The Critical Appraisal Skills Programme was used to appraise validity of the
research studies analyzed. The CASP checklist is an 11question series used to determine
if randomized control trials are appropriate to use in a systematic review. It is further
divided into three sections. The first section is to review the validity of the study. There
are five questions within the first section. The researcher answers the questions to help
determine if the results of the study are valid. The second section is to review the results
of the study. This section contains two questions. The researcher answers each question
to determine what the results of the study are. The last section is the application of the
study to the population at hand. There are three questions within this section. These
questions help to establish how the results can be applied to practice (CASP, 2017). The
checklist, shown on page 31, in its entirety provides a concise way to evaluate each
systematic review individually.
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Eligibility

Screening

Identification

PRISMA 2009 Flow Diagram
Records identified
through database
searching
(n = 5)

Additional records
identified through
other sources
(n = 0)

Records after duplicates
removed
(n =5)

Records screened
(n = 5)

Full-text articles
assessed for eligibility
(n = 5)

Included

Studies included in
qualitative synthesis
(n = 5)

Studies included in
quantitative synthesis
(meta-analysis)
(n = 5)

Records
excluded
(n = 0)

Full-text
articles
excluded,
with reasons
(n =0)
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Results
The completed flow diagram, ash shown on page 31, is a visual demonstrating
how the final five studies were chosen to implement in this systematic review. The initial
search term “Sevoflurane” was used and resulted in 18,466 studies. Additional search
terms including “Propofol” and “TIVA” narrowed the results to 285. Lastly, the terms
“immune” and “breast cancer” were added and narrowed the results to 5 studies. There
were no duplicate articles to exclude from this systematic review. After article screening,
none were excluded, as all of the five studies met inclusion criteria previously identified.
The remaining five articles were selected to complete this systematic review to determine
if total intravenous anesthesia versus Sevoflurane is more efficacious in limiting the
amounts of immune cells released during the perioperative period in breast cancer
patients.
Each of the studies reviewed for this systematic review have an explanation of the
results with the study findings clearly identified. Study specific data is shown in
Appendix A (Tables A1-A5). Information obtained for these tables include the study
design, purpose, location, sample size, and methods. Outcome data collection tables were
created to summarize the results of those studies. The tables are included in Appendix B
(Tables B1-B5). Specific findings include what types of immune cells were studied and
amounts of cells released in identified time intervals. Critical appraisal data tables
(Appendix C, Tables C1-C5) were used to assess the validity, reliability, and applicability
of the studies included in this systematic review. Lastly, a cross-study analysis data table
was used (Appendix D) comparing the results of each study.
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Individual Studies
The single-center, randomized, parallel group study by Yan et al. (2018)
(Appendix A, Table A-1) examined the effects of Propofol based TIVA and Sevoflurane
anesthetic on proangiogenic factors and further evaluated for a correlation between
proangiogenic factors released in occurrence free survival in breast cancer patients. A
total of 83 patients who underwent breast cancer surgery, specifically modified radical
mastectomy or breast conserving surgery, were divided into two groups. Group 1 (n=42)
was the Propofol based TIVA group. These patients received Propofol and Remifentanil
infusions for TIVA during the maintenance phase of anesthesia. Group 2 (n=41) was the
Sevoflurane inhalation anesthetic group. These patients received Sevoflurane for the
maintenance phase of anesthesia. Both group 1 and group 2 were induced with Fentanyl
2-3 µg/kg, Propofol 1-2 µg/kg, and paralyzed with Rocuronium 0.6 mg/kg. Fresh gas
flows of 2L/min were maintained on both groups as well as an [exhaled] carbon dioxide
level of 35-45 mmHg. Both groups had blood drawn at standardized times, specifically
preoperatively and postoperatively at the 24-hour mark.
Outcomes of the study done by Yan et al. (2018) (Appendix B, Table B-1)
showed that VEGF-C levels increased from 133 (80-205) to 140 (92-250) in group 1
(TIVA). There was a pre-post change value of 12 (-8-52) in this group. Group 2 had an
increase in VEGF-C values from 105 (87-193) to 174 (111-281) and a pre-post change
value of 3 (-3-47). The difference between groups’ VEGF-C values were not statistically
significant preoperatively (p=0.729) or postoperatively (p=0.177). The pre-post change
value, however, was statistically significant (p=0.008) in both groups. When comparing

TGF-b levels in group 1 preoperatively to postoperatively, those levels decreased from 29
198 (100-304) to 176. There was a change value of 13 (-17-51) in the TIVA group.
Group 2 experienced an increase in TGF-b levels when comparing preoperative values,
197 (131-318), to postoperative values, 211 (109-308). This group had a change value of
3 (-30 - 47). The levels of TGF-b were not statistically significant in the preoperative
(p=0.721), postoperative (p=0.794), or pre-post changes (p=0.582), when comparing the
two groups values. Group 1 had a recurrence free survival of 95% at the two-year mark.
Group 2 had a recurrence free survival of 75% at the two-year mark. When comparing
both groups, recurrence free survival was not statistically significant (p=0.221).
Utilizing the CASP questionnaire, (Appendix C, Table C-1), this study (Yan et
al., 2018) has a clearly focused issue. All patients involved were randomized and both
groups were similar at the start of the trial. Aside from the clinical intervention both
groups were treated equally throughout the study. In addition, the healthcare members
involved in measuring of the blood samples for the study were blinded as to which
intervention the patient received. The results of this study can be applied to adult females
undergoing breast cancer tumor removal that require general anesthesia. There are several
limitations to this study. First, Propofol was used for induction for both groups. Propofol
would have dissipated within 10-15 minutes after administration, but it is unclear if this
affected the results of this study. Secondly, the number of patients enrolled in this study
was small (n=83). Finally, this study was carried out in a single center.
The tri-center, prospective study by Ito et al. (2017) (Appendix A, Table A-2)
looked at the effect of anesthetic technique (Propofol based TIVA versus Sevoflurane) on
the immune response in patients undergoing breast cancer surgery in a day center or

hospital. A total of 37 patients who underwent breast cancer surgery, specifically, partial30
resection of the breast, sentinel lymph node biopsy with axillary lymph node dissection,
or total mastectomy, were divided into two groups. Group 1 (n=21) was the Propofol
based TIVA day center group. These patients received Propofol, lidocaine, and Pethidine
for TIVA during the maintenance phase of anesthesia. Group 2 (n=16), was the
Sevoflurane with Propofol or Propofol with opioid TIVA hospitalized group. Seven
patients (n=7) received TIVA of Propofol (1-3µg/mL with Remifentanil (0.25 µg/kg/min)
for maintenance while Propofol (3µg/mL) and Fentanyl (1-2µg/kg) were administered at
induction. Four patients (n=4) received TIVA with Propofol (3µg/mL) for maintenance
with Fentanyl (1-2µg/kg) and Propofol (2µg/kg) given at induction. Four patients (n=4)
received Sevoflurane inhalation anesthetic (1.0-5.0%) and Remifentanil (0.25 µg/kg/min)
drip for maintenance with Propofol (2µg/kg) and Fentanyl (1-2 µg/kg) given at induction.
One patient (n=1) was maintained with Sevoflurane (1.0-5.0%) and given Propofol
(3µg/mL) and Fentanyl (1-2 µg/kg) at induction. All patients in the hospitalized group
were given Rocuronium (0.6 mg/kg) for paralysis and ventilated with a mixture of 1:2-3
O2 and air. Both groups had blood drawn at standardized times, specifically,
preoperatively, and postoperatively at the 24-hour mark.
Outcomes of the study done by Ito et al. (2017) (Appendix B, Table B-2) shows
the median change values of NK Cell activity, CD4/8 T Cell Ratio, and IL-6 levels in the
preoperative, postoperative, and 24-hours postoperatively. In Group 1 (day surgery TIVA
group) median NK Cell activity preoperatively was 30.5± 9.2 and then fell to 29.0± 9.0.
At the 24-hour mark the median NK Cell level rose to 32.0± 7.5. In Group 2 (hospitalized
TIVA or Sevoflurane with opioid group) median NK cell activity was 24.5± 13.8. This

value rose to 31.0± 12.3 in the postoperative period and then fell to 25.0± 9.5 at the 24- 31
hour postoperative mark. In group 1 the CD4/8 T Cell Ratio median value rose steadily
throughout all three time periods. Values started at 1.31± 0.32, increased to 1.53± 0.64,
and rose to 1.67± 0.34 by the 24-hour postoperative time period. In Group 2 CD4/8 T
Cell Ratio median values started at 1.63± 0.55, decreased to 1.23± 0.16, and then
increased almost to baseline with a median value of 1.61± 0.68. In group 1 IL-6 median
values started at 1.1± 0.5, fell to 1.0± 0.65, and then increased to 5.4± 1.35 in the 24-hour
postoperative time frame. Group 2 showed an increasing trend of median IL-6 values
across all three time periods. Initially median values were measured at 2.0± 1.94. In the
postoperative period those values increased from 3.9± 2.95 postoperatively to 15.3± 7.15
in the 24-hour postoperative period. There was no statistical validity testing done with
these values.
Utilizing the CASP questionnaire, (Appendix C, Table C-2), this study (Ito et al.,
2017) has a clearly focused issue, patients were not randomized, both groups were
similar at the start of the trial, and aside from the clinical intervention both groups were
treated equally throughout the study. The healthcare members involved were not blinded
to the intervention that the patient received. The results of this study might be applied to
adult females undergoing breast cancer tumor removal that require general anesthesia.
There are several limitations to this study. First, propofol was used for induction for both
groups. Propofol would have dissipated within 10-15 minutes after administration, but it
is unclear if this could have affected the results of this study. Secondly, the number of
patients enrolled in this study is small (n=37). Third, this study did not clearly separate
the two methods of delivery of anesthesia. Patients were grouped according to the setting

in which they received care, either hospitalized or a day surgery center, and not by the 32
medication they received for maintenance of anesthesia.
The single center, randomized, retrospective analysis of an ongoing randomized
clinical trial study by Buggy et al. (2018) (Appendix A, Table A-3) sought to determine if
the inflammatory response would be less in breast cancer patients who received propofol
based TIVA than those who received sevoflurane/ opioid based anesthesia for removal of
cancerous breast tumors. The researchers measured the amounts of neutrophillymphocyte ratio, white blood cell count, platelet count, and platelet-lymphocyte ratio. A
total of 116 patients who underwent unilateral mastectomy, bilateral mastectomy, and
lumpectomy with axillary node dissection that were enrolled in another ongoing
randomized clinical trial were enrolled and divided into two groups. Group 1 (n=59)
received propofol TIVA with a paravertebral nerve block. The paravertebral block was
given as a one-time injection in the T1-T5 interspaces or an injection with thoracic
epidural catheter placement, in the T2-T4 interspace, for continued postoperative pain
management. Those that received an epidural catheter were administered a test dose of
1.5% Lidocaine and 1:200,000 epinephrine and then followed with either bupivacaine
0.5% or ropivacaine 0.5%. Those that were given multilevel injections were administered
5mL of 0.75% bupivacaine. Postoperative pain was managed with either the
paravertebral block or non-steroidal anti-inflammatory drugs (NSAID’s), morphine for
intractable pain, and transitioned onto NSAID’s and paracetamol by the 24-hour
postoperative mark. Group 2 (n=57) had sevoflurane with an opioid administered as the
chosen anesthetic. For this group, anesthesia was induced using fentanyl 2-4 µg/kg and
propofol 1-3 mg/kg. Sevoflurane and fentanyl were given to maintain heart rate and

blood pressure within 20% of preoperative values. Morphine 0.1mg/kg was administered33
at the end of the surgery. Postoperative pain was managed with morphine or similar long
acting opioid with a transition to paracetamol and NSAID by the 24-hour mark. Both
groups had blood drawn at standardized times, specifically, preoperatively, and
postoperatively.
Outcomes of the study done by Buggy et al. (2018) (Appendix B, Table B-3)
shows the amounts of white blood cells, neutrophils, lymphocytes, platelets, neutrophillymphocyte ratio, platelet-lymphocyte ratio, as well as the change in the neutrophillymphocyte ratio in the preoperative and postoperative period. In the preoperative period
group 1 median white blood cell level was 7.4, while group 2 had a median white blood
cell level of 7.2. When comparing these two median values there was no statistically
significant difference. In group 1, the median neutrophil count was 4.7 whereas the
median value for group 2 was 4.6 in the preoperative period. There was no statistically
significant difference between the groups. In the preoperative period the median
lymphocyte count was 2.0, while group 2 had a median value of 1.9. There was no
statistically significant difference between the groups. Median levels of platelets in the
preoperative period for group 1 was 292 and 265 for group 1. There was no statistically
significant difference between these groups. The neutrophil-lymphocyte ratio median
value in group 1 was 3.0 and 4.0 for group 2 and was not statistically significant
different. The platelet-lymphocyte ratio median value was 142 for group 1 in the
preoperative period, and was 148 for group 2, with no significant difference.
In the postoperative period, group 1 and group 2 had a white blood cell count
median value of 9.0. In the postoperative period, group 1 had a neutrophil count median
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value of 6.4, whereas group 2 had a median value of 6.5. Group 1 had a median
lymphocyte count of 1.8 and group 2 had a median lymphocyte count of 1.7. In the

postoperative period group 1 had a median platelet value of 268. In the same time period,
group 2 had a median platelet count of 237. The median neutrophil-lymphocyte ratio was
significantly different (p=0.001) between the two groups (group 1: 3.0 versus group 2:
4.0). Similarly, the change in median neutrophil-lymphocyte count from the preoperative
time period to the postoperative time period was also significant (p=0.001), with group 1
at 30% and group 2 at 82%. Finally, the median platelet-lymphocyte count in the
postoperative period was 148 in group 1 and group 2 (Buggy et al., 2018).
Utilizing the CASP questionnaire, (Appendix C, Table C-3), this study Buggy et
al. (2018) has a clearly focused issue. Patients were randomized and both groups were
similar at the start of the trial. Aside from the clinical intervention, both groups were
treated equally throughout the study. Whether the healthcare team was blinded to the
treatment was not clear. The results of this study may be applied to adult females
undergoing breast cancer tumor removal that require general anesthesia. There are several
limitations to this study. First, propofol was used for induction for the sevoflurane group
(group 2). Propofol would have dissipated within 10-15 minutes after administration, but
it is unclear if this could have affected the results of this study. Secondly, blood samples
postoperatively were taken at different times. All patients had all blood samples taken
within 72 hours. However, when within the 72 hours the blood samples were taken
varied.
The single-center, randomized, control trial by Oh et al. (2018) (Appendix A,
Table A-4) compared the changes in amounts of cluster differentiation of regulatory T

cells in patients receiving propofol based TIVA or sevoflurane for breast cancer surgery.35
The researcher specifically measured the amounts of cluster differentiation enzyme 39
(CD39) and cluster differentiation enzyme 73(CD73) on regulatory T cells as well as the
median neutrophil-lymphocyte ratio. A total of 201 women who underwent breast cancer
surgery were divided into two groups. Group 1 (n=99) was the propofol based TIVA
group. This group received propofol TIVA with a target concentration of 40 µg/mL using
a TCI device. Group 2 (n=102) was the sevoflurane group. This group received
thoipental5mg/kg for induction. Maintenance anesthesia was achieved with sevoflurane
inhalation anesthetic with a Bispectral Index (BIS) monitoring goal of 40-60 with
remifentanil drip at a goal concentration of 5.0ng/mL. Both groups received lidocaine
0.5mg/kg, rocuronium 0.6 mg/kg, ketorolac 0.5mg/kg, 0.03mg/kg neostigmine, and
0.008mg/kg glycopyrrolate were given to both groups. Mean arterial pressure was
maintained at 20% of baseline for both groups. Both groups had blood drawn at
standardized times, specifically, preoperatively, postoperatively by the 1-hour mark, and
again at the 24-hour mark.
Outcomes of the study done by Oh et al. (2018) (Appendix B, Table B-4) showed
that expression of CD39 decreased overall in group 1 with values in the preoperative time
period of 17.1%, 16.7%± 7.6% in the first hour postoperative, and 16.9% in the 24-hours
postoperatively. CD39 was expressed 17.6% in the preoperative period, 16.5%± 7.9% in
the first hour postoperatively, and returned to baseline (17.6%) within 24-hours
postoperatively in group 2. Frequency of CD73 expression in group 1 was 19.4% in the
preoperative period, 18.5% in the first hour postoperatively, and 19.2% in the 24-hours
postoperatively. In group 2 frequency of CD73 expression was shown to increase across

all three time intervals. The preoperative value was 19.0%, with an increase in expression36
to 19.2%, and finally 19.6% by the 24-hour time interval. Although there was an increase
in value, this was not statistically significant (p=0.658). In group 1 the neutrophillymphocyte ratio increased from 1.55 in the preoperative time period to 1.62 in the first
hour postoperatively. The neutrophil-lymphocyte ratio was not measured at the 24-hour
postoperative mark. In group 2 the neutrophil-lymphocyte ratio decreased from 1.76
preoperatively to 1.68 at the 1-hour postoperative mark.
Utilizing the CASP questionnaire, (Appendix C, Table C-4), this study by Oh et
al. (2018) has a clearly focused issue. All patients involved were randomized. Both
groups were similar at the start of the trial and aside from the clinical intervention both
groups were treated equally throughout the study. The healthcare members involved in
measuring the blood samples for the study were blinded as to which intervention the
patient received. The results of this study can be applied to adult females undergoing
breast cancer tumor removal that require general anesthesia. There are several limitations
to this study. First, opioids and ketorolac that were used could potentially mask the pure
effect of sevoflurane or propofol TIVA on the values measured. Secondly, the use of
immune markers, cluster differentiation 39 and 73, have not been proven to be a
contributor to poor prognosis in humans as it has in animal studies (Antonioli et al.,
2013). Finally, this study was carried out in a single center.
The single-center, randomized, double blind control trial by Kim et al. (2018)
(Appendix A, Table A-5) sought to identify the effect of propofol TIVA versus
sevoflurane on natural killer cells, cytotoxic T cells, IL-6 levels,IL-10, tumor necrosis
factor-a (TNF-a), and apoptosis rates in patients undergoing surgery for breast cancer. A

total of 44 women who underwent breast cancer surgery were divided into two groups. 37
Group 1 (n=23) was the propofol based TIVA group. This group received propofol TIVA
with a target concentration of 40 µg/mL using a TCI device. Group 2 (n=21) was the
sevoflurane group. This group received thoipental 5mg/kg for induction. Maintenance
anesthesia was achieved with sevoflurane inhalation anesthetic with a Bispectral Index
(BIS) monitoring goal of 40-60 with remifentanil drip at a goal concentration of
5.0ng/mL. Both groups received rocuronium 0.6 mg/kg, ketorolac 0.5mg/kg, 0.03mg/kg
neostigmine, and 0.008mg/kg glycopyrrolate. Mean arterial pressure was maintained at
20% of baseline or greater than 60mmHg for both groups. Both groups had blood drawn
at standardized times, specifically, preoperatively, postoperatively by the 1-hour mark,
and again at the 24-hour mark.
Outcomes of the study done by Kim et al., (2018) (Appendix B, Table B-5)
showed that in group 1 median TNF-a decreased initially but rose overall with values in
the preoperative time interval of 413 (390-470), 390 (390-430) at the one hour
postoperative time interval, and 420 (390-430) by the 24-hour time interval. In group 2
TNF-a levels followed the same pattern. Median values in the preoperative time interval
were 404± 42, 400 (370-455) by the 1-hour postoperative mark, and then 417± 25 in the
24-hour postoperative time frame. When comparing values of TNF-a in the preoperative
period between group 1 and group 2 there was no statistical significance (p=0.175).
Furthermore, there was no statistical significance when comparing TNF-a values
between group 1 and group 2 in either postoperative time period with values of p=0.953
at the 1-hour mark and p=0.958 at the 24-hour mark. Median levels of IL-6 in the
preoperative time period were 90 for both groups 1 and 2. This was not statistically
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significant with a value of p=0.524. By the one-hour postoperative mark, group 1 showed
an increase in levels of IL-6 with median levels measuring 100 (90-100), while group 2
values remained the same at 90 (90-100). By the 24-hour postoperative mark, Il-6 levels
were 90 (90-100) for both groups. Median levels of Il-10 fell overall in group 1. In the
preoperative time period median values of Il-10 were 490 (450-550). In the 1-hour
postoperative time period median values remained the same, 490 (440-550). By the 24hour time frame the median IL-10 values fell to 470 (440-500) in group 1. In group 2
median levels of IL-10 were 470 (445-525) preoperatively, 450 (435-520) at the 1-hour
postoperative mark, and 470 (440-500) by the 24-hour postoperative mark. When
comparing median values of IL-10 from group 1 to group 2, none of the values proved to
be statistically significant with values of p=0.430, p=0.340, and p=960.
Utilizing the CASP questionnaire, (Appendix C, Table C-4), this study by Kim et
al., (2018) has a clearly focused issue. All patients involved were randomized and both
groups were similar at the start of the trial. Aside from the clinical intervention both
groups were treated equally throughout the study. The healthcare members involved in
measuring of the blood samples for the study were double “blind” as to which
intervention the patient received. The results of this study can be applied to adult females
undergoing surgery to remove tumors caused by breast cancer. There are several
limitations to this study. First, opioids and ketorolac that were used could potentially
mask the pure effect of sevoflurane or propofol TIVA on the values measured. Secondly,
there were very few women enrolled in the study (n=44). Lastly, this study was
conducted at a single center.
Next, the summary and conclusions will be presented.

Summary and Conclusions
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Metastasis of cancerous cells, specifically breast cancer cells, has been shown to
increase chances of mortality. According to the National Cancer Institute (2018) breast
cancer survival was about 90% overall. Patients with distant metastasis had a survival
rate of 27% and those with regional metastasis had an 85% survival rate. This shows that
the more metastasis to distant areas, the lower the chance of survival of the patient
(American Cancer Society, 2019). It is theorized that surgery can increase the amount of
metastasis (Simmons et al., 2017). Therefore, limiting the amount of metastasis caused
from breast cancer surgery would increase chances of survival.
Propofol is a phenol derivative that has been shown have several benefits that
may aid in limiting immune dysfunction in breast cancer patients related to surgery.
Propofol has been shown to limit NK dysfunction (Dilger, 2018) and aid in infiltration of
the cancer cells by the immune system’s own NK cells and T lymphocytes (Buggy et al.,
2015). In addition, propofol has also been shown to have better long-term survival rates
when compared to volatile agents such as sevoflurane (Jhanji et al., 2016). Sevoflurane, a
volatile inhalation anesthetic, has been shown to have a higher cancer recurrence rates in
breast cancer patients (Lee et al., 2016). When comparing sevoflurane to propofol base
TIVA, patients who received sevoflurane had a lower survival rate at the one-year mark
(Andreasson et. al., 2014).
The purpose of this systematic review was to examine if Total Intravenous
Anesthesia versus Sevoflurane is more efficacious in limiting the amounts of immune
cells released during the perioperative period in breast cancer patients. A comprehensive
literature review was completed using Pubmed, CINHAL, and Medline. This literature
review focused on immunity, the immune system’s role in neoplasia and metastasis,

breast cancer, surgical approaches for breast cancer, and both propofol and sevoflurane’s40
effect on immunity involving breast cancer surgery. A theoretical framework was chosen
to aid in the identification of eligible studies based on specific inclusion criteria.
PRISMA was the theoretical framework chosen. It is a 27-item checklist and four-phase
flowchart (Altman, et al., 2009).
Individual study analysis was completed on the final five studies meeting criteria.
Study specific data tables were created outlining key information from each study. Data
outcome tables were created to determine the efficacy of propofol based TIVA and
sevoflurane on limiting the amounts of immune cells released during the perioperative
period in breast cancer patients. Next, critical appraisal of individual RCT’s was
performed utilizing the Critical Appraisal Skills Programme (CASP) checklist. Last, a
cross study analysis table was created to compare the types of immune cells released
during the perioperative period.
There were several limitations noted when completing this systematic review.
Some studies were not a randomized control study by design. Specifically, one study was
a retrospective study of an ongoing randomized control trial and two studies were
prospective control trials. The other two studies were randomized control trials.
Secondly, two of the studies were not blinded. A third limitation is lack of consistence in
which immune mediator was measured. Each study measured different immune cells and
immune mediators; therefore there is a lack of congruency in results for comparison.
Lastly, each study took blood samples at different times. This lack of consistency in time
intervals for blood draws makes it difficult to draw definitive conclusions.

The findings of this systematic review determined that propofol based TIVA
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increases recurrence free survival, however there is negligible differences in the immune
response between propofol based TIVA and sevoflurane inhalation anesthetic for women
undergoing surgery for breast cancer tumor excision.
Next, the recommendations and implications for practice will be presented.

Recommendations and Implications for Advanced Nursing Practice
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When weighing options in treatment for breast cancer, in many cases, the benefits
of surgery outweigh the risks. Once the decision has been made to proceed with surgery,
options for surgical approach are planned with the patient and surgeon in collaboration to
choose the safest and most effective option. On the day of surgery, the anesthesia
provider will meet the patient, assess them, and create an individualized anesthetic plan
(Nagelhout & Plaus, 2018). The anesthesia provider will consider the patient’s
comorbidities, airway anatomy, length and type of surgery, and postoperative pain
management when selecting an anesthetic plan (Nagelhout & Plaus, 2018). However,
with patients undergoing surgery for breast cancer, the anesthesia provider should also
individualize a plan that will increase the patient’s chances of survival from breast
cancer.
It is paramount that as anesthesia providers we always plan with the end in mind.
In this case, the end should not be limited to the patients discharge from the recovery
room. The end goal should be to increase chance of survival for the patient. Propofol has
been shown to limit the amount of NK cell suppression in murine models (Bar-Yosef et
al., 2003) and may increase the survival rate of patients undergoing breast cancer surgery
at the two-year mark (Yan et al., 2018). However, as demonstrated in this systematic
review, propofol may not have a noticeable effect on other immune mediators such as IL6, IL-10, neutrophils, and platelet levels. Sevoflurane has been shown to elicit an immune
response, but its effects may not be significant. Continued research is needed in this area
to determine which anesthetic choice will lead to better patient outcomes. In addition,

anesthesia providers should continue to be educated in immunology and anesthetic
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impact on breast cancer patients.
The overall recommendation from this systematic review is that anesthesia
providers should continue to individualize an anesthetic plan that places the patient’s
safety, comfort, and surgical success first. This systematic review has demonstrated that
there is not a clear choice as to whether propofol based TIVA or sevoflurane will increase
survivability and limit the immune response in this patient population. More research
should be done in this area to identify if one method of anesthesia is superior to the other.
Until such results are available, anesthesia providers should maximize survivability by
limiting the surgical stress response in a way that also accounts for patient safety, pain
management, and surgical success in breast cancer patients undergoing surgery for tumor
removal.
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Appendix A
Table A-1
Study Specific Data
Sun, L., Wang, B.N., Yan, T., Zhang, G.H., & Zheng, H. (2018). Effects of propofol/remifentanil-based total intravenous anesthesia versus sevoflurane-based inhalational anesthesia
on the release of VEGF-C and TGF-β and prognosis after breast cancer surgery: a prospective, randomized and controlled study. BMC Anesthesiology, 18(1), N.PAG. https://doiorg.ric.idm.oclc.org/10.1186/s12871-018-0588-3

AIM/PURPOSE
1.Research to
discover what
effect Propofol
based TIVA and
Sevoflurane
anesthetic
techniques have on
proangiogenic
factors.
2. How the amount
of the
proangiogenic
factors released
may have a
correlation with
recurrence-free
survival and
overall survival
rates in patients
undergoing breast
cancer resection
surgery.

DESIGN
Single center,
controlled,
parallel-group
clinical trial, with
randomization.
Group 1-Propofol
remifentanilbased TIV A
Group 2Sevoflurane
inhalation
anesthetic

SITE
Cancer Hospital
of Chinese
Academy of
Medical Sciences

SAMPLE
90 patients were
assed for eligibility;
7 were excluded for a
total of 83 included
in the study.
All patients
underwent a
modified radical
mastectomy (MRM)
or breast conserving
surgery (BCS).
Group 1-(n=42)
Propofol/remifentanil
Group 2-(n=41)
Sevoflurane

METHODS
Patients were
randomized into the
two groups.
Group 1- Propofol
drip3-6mg/kg/h and
Remifentanil 0.10.2µg/kg/min
Group 2-1.5-2%
Sevoflurane with BIS
values of 40-60.

PROCEDURES
Group 1 and 2 were
induced with Fentanyl 23µg/kg, Propofol 12mg/kg, and
Rocuronium 0.6 mg/kg.
LMA inserted,
hemodynamics
monitored, carbon
dioxide maintained 3545 mmHg, and a fresh
gas flow of 2L/min
oxygen.
Fentanyl bolus’ given
intraoperatively as
needed in both groups.
NSAIDS given for pain
management.
Group 1-Propofol and
Remifentanil drips for
maintenance phase.
Group 2-Sevoflurane for
maintenance phase.
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Table A-2
Study Specific Data
Ito, M., Kadoya, T., Funaoka, Y.,Kawai, A., Kim, R., Wakisaka, M.,Y., Ohtani, S., & Okada, M. (2017). Differences in immune response to anesthetics used for day surgery versus
hospitalization surgery for breast cancer patients. Clinical & Translational Medicine, 6(1), 1–8. Doi: 10.1186/s40169-017-0163-4 https://doi-org.ric.idm.oclc.org/10.1186/s40169017-0163-4

AIM/PURPOSE
To discover what
effect anesthetic
technique used
(TIVA versus
Sevoflurane
inhalation
anesthetic) has on
the immune
response in
patients
undergoing
breast cancer
surgery in a day
center versus
hospitalization.

DESIGN
SITE
Tri-center, prospective study. Day center:
Hiroshima Mark
Group 1-Day surgery,
Clinic
Lidocaine/Propofol/Pethidine
(TIVA)
Hospitalization:
Hiroshima City
Group 2-Hospitalized,
Hospital or
Sevoflurane/Propofol,
Hiroshima
systemic-opioid-based
University
Hospital

SAMPLE
Thirty-seven patients
who underwent
partial resection of
the breast (Bp),
sentinel lymph node
biopsy (SNB), (Bp)
with axillar lymph
node dissection (Ax),
and a total
mastectomy with Ax.
Group 1-(n=21)
Day surgery,
lidocaine, Propofol,
Pethidine (TIVA)
Group 2-(n=16)
Hospitalized
Sevoflurane/Propofol,
or Propofol systemicopioid-based
anesthesia (TIVA)

METHODS
Patients were placed into
groups based on hospital
preference, and thus the
anesthetic technique that
coordinated with the chosen
site. Blood levels were taken
before, after, and 24 hours
after surgery.
Group 1- induction with
1mg.kg Propofol and 35mg
Pethidine. Maintenance was
achieved via Propofol TIVA
6-8mg/kg/h and 50-100mg of
0.5% Lidocaine for
localization of the area.
Group 2- Selection of
technique was at the
discretion of the
anesthesiologist. Some
patients (n=4) received
Propofol and Fentanyl for
induction, Sevoflurane gas
and Remifentanil drip for
maintenance. Some (n=7)
received Propofol and
Fentanyl for induction,
Remifentanil/Fentanyl (TCI)
TIVA for maintenance. Some
patients(n=4) received
Propofol and Fentanyl
induction, Propofol and
Fentanyl (TCI) TIVA for
maintenance. Only one
patient received Propofol and
Fentanyl at induction and
Sevoflurane for maintenance.

PROCEDURES
Immune response
was evaluated using
the blood samples.
Specifically
measured was NK
cell activity, CD4/8
T cell ratios, and
levels of cytokines,
IL-6 and IL-10
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Appendix A
Table A-3
Study Specific Data
Buggy, D. J, Burns, D., Ní Eochagáin, A., Riedel, B., & Sessler, D. I. (2018). The effect of
anaesthetic technique during primary breast cancer surgery on neutrophil-lymphocyte
ratio, platelet-lymphocyte ratio and return to intended oncological therapy. Anaesthesia, 73(5), 603–611. https://doi-org.ric.idm.oclc.org/10.1111/anae.14207

AIM/PURPOSE
To determine if the
inflammatory
response would be
less in breast
cancer patients who
received Propofol
(TIVA) and
paravertebral block
versus Sevofluraneopioid anesthesia
for breast cancer
surgery.
Specifically
measured was the
neutrophillymphocyte ratio,
white cell count,
neutrophil count,
platelet count, and
plateletlymphocyte ratio.

DESIGN
Single center,
retrospective
analysis of an
ongoing randomized
control trial
Group 1-Propofol
(TIVA)/paravertebral
group
Group 2Sevoflurane/opioid

SITE
Mater University
Hospital

SAMPLE
116 patients who
underwent unilateral
mastectomy, bilateral
mastectomy,
lumpectomy with
axillary node
clearance.
Group 1-(n=59)
Propofol
(TIVA)/paravertebral
group
Group 2-(n=57)
Sevoflurane/opioid
group

METHODS
Patients were
randomized into the
two groups.
Group 1- Paravertebral
block with catheter
placement, 10-20mL
dose of 0.5%
Bupivicaine or 0.5%
ropivacaine with
Epinephrine, at the end
of the surgery 6-10mL
of either solution were
titrated in, Propofol
(TIVA) 6090µg/kg/min
Group 2-induction with
1-3 µg/kg Fentanyl, 24mg/kg Propofol,
maintenance using
Sevoflurane, Morphine
0.1mg/kg given at the
end of surgery.

PROCEDURES
Patients were
randomized into either
anesthetic group. Charts
were reviewed and
level of neutrophillymphocyte ratio was
noted. These levels
were taken before and
after surgery.
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Appendix A
Table A-4
Study Specific Data
Kim, S.H., Lee, J.Y., Lee., S.H., Oh, C.S., Park, H.J., Piao, L., H., Seo, E.H., & Yoon, T.G. (2018b). Effect of Equipotent Doses of Propofol versus
Sevoflurane Anesthesia on Regulatory T Cells after Breast Cancer Surgery. Anesthesiology, 129(5), 921–931. https://doiorg.ric.idm.oclc.org/10.1097/ALN.0000000000002382
AIM/PURPOSE The
purpose of the study
was to compare the
amount of changes in
cluster differentiation
on regulatory T cells
in patients receiving
Propofol based TIVA
and Sevoflurane for
breast cancer surgery.
Specifically, the
researchers compared
cluster differentiation
of enzyme 39 and 73
on regulatory T cells.
Amount of NK cells,
cytotoxic T cells,
cytokines, and
neutrophil-tolymphocyte ratio were
also measured.

DESIGN
Single center,
randomized control trial.

SITE
Konkuk Universiry
Medical Center,
Korea

SAMPLE
201 women undergoing
surgery for breast cancer.

METHODS
Patients were randomized
into the two groups.

PROCEDURES
Patients were randomized
into one of the two groups.

Group 1-Propofol
(TIVA)

Group 1- (n=99) Propofol
TIVA group

Group 2-Sevoflurane

Group 2-(n=102)
Sevoflurane group

Blood samples were
obtained prior to
induction and 24 hours
postoperatively.

Group 1-revieved Propofol
(TCI) TIVA with a goal of
BIS monitoring 40-60 and
MAP 20% of baseline or
greater than 60mmHG for
maintenance phase.

Lidocaine was given, BIS
monitoring was
performed, and
Rocuronium was given to
all patients.

Group 2 received Thiopental
5mg/kg in addition to
Rocuronium and Lidocaine
for induction. For
maintenance these patients
were given Sevoflurane gas
with a BIS monitoring 40-60
and MAP 20% of baseline or
greater than 60mmHG.
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Table A-5
Study Specific Data
Kim, S.H., Lee, J. Y., Lee, S.H., Lim, J.A., Oh, C.S., Yoon, T.G., Yang, J. H., & Yoo, Y.B. (2018). The effect of propofol and sevoflurane on cancer cell, natural killer cell, and
cytotoxic T lymphocyte function in patients undergoing breast cancer surgery: an in vitro analysis. BMC Cancer, 18, 1. https://doi-org.ric.idm.oclc.org/10.1186/s12885-018-4064-8

AIM/PURPOSE
The researchers
sought to identify
the effect of
Propofol TIVA
versus Sevoflurane
on natural killer
cells, cytotoxic T
cells, and
apoptosis rates in
patients
undergoing
surgery for breast
cancer.
Additionally,
cytokine tumor
necrosis factor-a,
IL-6, and IL-10
were measured.

DESIGN
Single center,
prospective, double
blind, randomized
control trial.
Group 1-Propofol
(TIVA)
Group 2-Sevoflurane

SITE
Konkuk
Universiry
Medical Center,
Korea

SAMPLE
44 women
undergoing surgery
for breast cancer.
Group 1- (n=23)
Propofol TIVA
group
Group 2-(n=21)
Sevoflurane group

METHODS
Patients were randomized
into the two groups.
Blood samples were
obtained prior to
induction, 1- hour
postoperatively, and 24hours postoperatively.
Anesthesia was induced.
BIS monitoring was used
on both groups. In
addition to the given
anesthetic, both groups
received Ketorolac for
pain management during
the anesthetic.
Group 1-received
Propofol (TCI) TIVA
with a goal of BIS 40-60.
Group 2- received
induction with a
Thiopental 5mg/kg,
Remifentanil, and
Rocuronium for
induction. Sevoflurane
was administered for
maintenance with a goal
of BIS 40-60.

PROCEDURES
Patients were randomized
into one of the two groups.
After induction group
received Propofol (TCI)
TIVA with a goal of BIS
monitoring 40-60 and MAP
20% of baseline or greater
than 60mmHG for
maintenance phase.
Group 2- Received
Sevoflurane gas with a BIS
monitoring 40-60 and MAP
20% of baseline or greater
than 60mmHG.
Neuromuscular blockade
was reversed with
neostigmine and
glycopyrrolate at the
termination of the anesthetic
for both groups.
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Table B-1
Outcome Data Tables
Sun, L., Wang, B.N., Yan, T., Zhang, G.H., & Zheng, H. (2018). Effects of propofol/remifentanil-based total intravenous anesthesia versus sevoflurane-based inhalational
anesthesia on the release of VEGF-C and TGF-β and prognosis after breast cancer surgery: a prospective, randomized and controlled study. BMC Anesthesiology, 18(1),
N.PAG. https://doi-org.ric.idm.oclc.org/10.1186/s12871-018-0588-3

Preoperative
Values
VEGF-C

Group 1-TIVA

Group 2-Sevoflurane

P Value

133 (80-205)

105 (87-193)

p=0.729

TGF-b

198 (100-304)

197 (131-318)

p=0.721

Postoperative Values (24 hours)
VEGF-C

140 (92-250)

174 (111-281)

p=0.177

TGF-b

176 (116-361)

211 (109-308)

p=0.794

Pre-Post Changes
VEGF-C

12 (-8-52)

50 (21-108)

p=0.008

TGF-b

13 (-17-51)

3(-30-47)

p=0.582

95%

75%

p=0.221

Recurrence Free
Survival at 24
months
postoperatively
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Table B-2
Outcome Data Tables
Ito, M., Kadoya, T., Funaoka, Y.,Kawai, A., Kim, R., Wakisaka, M.,Y., Ohtani, S., & Okada, M. (2017). Differences in immune response to anesthetics used for day surgery
versus hospitalization surgery for breast cancer patients. Clinical & Translational Medicine, 6(1), 1–8. Doi: 10.1186/s40169-017-0163-4 https://doiorg.ric.idm.oclc.org/10.1186/s40169-017-0163-4

Changes in Median
Values
Preoperatively
NK Cell
Activity
CD4/8 T Cell
Ratio
IL6

Group 1-Day surgery, Lidocaine/Propofol/Pethidine
(TIVA) (n=21)

Group 2-Hospitalized, Sevoflurane/Propofol, systemic-opioid-based
(n=16)

30.5 ± 9.2

24.5 ± 13.8

1.31 ± 0.32

1.63 ± 0.55

1.1 ± 0.5

2.0 ± 1.94
Changes in Median Values Postoperatively

NK Cell
Activity
CD4/8 T Cell
Ratio
IL-6

29.0 ± 9.0

31.0 ± 12.3

1.53 ± 0.64

1.23 ± 0.16

1.0 ± 0.65

3.9 ± 2.95
Changes in Median Values (24 hours)

NK Cell
Activity
CD4/8 T Cell
Ratio
IL-6

32.0 ± 7.5

25.0 ± 9.5

1.67 ± 0.34

1.61 ± 0.68

5.4 ± 1.35

15.3 ± 7.15
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Table B-3
Outcome Data Tables
Buggy, D. J, Burns, D., Ní Eochagáin, A., Riedel, B., & Sessler, D. I. (2018). The effect of
anaesthetic technique during primary breast cancer surgery on neutrophil-lymphocyte
ratio, platelet-lymphocyte ratio and return to intended oncological therapy. Anaesthesia, 73(5), 603–611. https://doi-org.ric.idm.oclc.org/10.1111/anae.14207

Preoperative Median
Values

Group 1-Propofol/Paravertebral TIVA
(n=59)
7.4

Group 2-Sevoflurane/Opioid
(n=57)
7.2

P Value

4.7
2.0
292
3.0

4.6
1.9
265
4.0

p=0.825
p=0.915
p=0.565
p=0.850

142

148

p=0.640

9.0

9.0

p=0.900

Neutrophil
×109.l−1

6.4

6.5

p=0.885

Lymphocyte
×109.l−1

1.8

1.7

p=0.860

Platelets
×109.l−1

268

237

p=0.610

3.0

4.0

p=0.001

30%

81%

p=0.001

148

148

p=0.885

White Cell
Neutrophil
Lymphocyte
Platelets
NeutrophilLymphocyte
Ratio
PlateletLymphocyte
Ratio
Postoperative Median
Values (Within 72 hours)
White Cell
×109.l−1

NeutrophilLymphocyte
Ratio
Change in
NeutrophilLymphocyte
Ratio
Platelet-Lymphocyte
Ratio

p=0.850
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Table B-4
Outcome Data Tables
Kim, S.H., Lee, J.Y., Lee., S.H., Oh, C.S., Park, H.J., Piao, L., H., Seo, E.H., & Yoon, T.G. (2018b). Effect of Equipotent Doses of
Propofol versus Sevoflurane Anesthesia on Regulatory T Cells after Breast Cancer Surgery. Anesthesiology, 129(5), 921–931.
https://doi-org.ric.idm.oclc.org/10.1097/ALN.0000000000002382
Group 1Propofol (TIVA)
n=99

Preoperative Value

1-Hour Post Procedure

24 Hours Post
Procedure

P Value

Frequency of
CD39
Expression
Frequency of
CD73
Expression
Median
Value:
NeutrophilLymphocyte
Ratio
Group 2- Sevoflurane
N=102

17.1%

16.7 ± 7.6%

16.9%

p = 0.680

19.4%

18.5%

19.2%

p = 0.658

1.55

1.62

17.6%

16.5 ± 7.9%

17.6%

p = 0.680

19.0%

19.2%

19.6%

p = 0.658

1.76

1.68

Frequency of
CD39
Expression
Frequency of
CD73
Expression
Median
Value:
NeutrophilLymphocyte
Ratio

p=0.202

p=0.883
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Table B-5
Outcome Data Tables
Kim, S.H., Lee, J. Y., Lee, S.H., Lim, J.A., Oh, C.S., Yoon, T.G., Yang, J. H., & Yoo, Y.B.
(2018a). The effect of propofol and sevoflurane on cancer cell, natural killer cell, and cytotoxic T lymphocyte function in patients undergoing breast cancer surgery: an in vitro
analysis. BMC Cancer, 18, 1. https://doi-org.ric.idm.oclc.org/10.1186/s12885-018-4064-8

Preoperative
Median
Value:
Group 2Sevoflurane
(n-21)

P Value

1-Hour Post
Procedure
Median
Value:
Group 1

1-Hour Post
Procedure
Median
Value:
Group 2

P Value

24 Hours
Post
Procedure
Median
Value:
Group 1

24 Hours
Post
Procedure
Median
Value:
Group 2

P Value

TNF-a

Preoperative
Median
Value:
Group 1Propofol
(TIVA)
(n=23)
410 (390-470)

404 ± 42

p=0.175

390 (390430)

400 (370455)

p=0.953

420 (390430)

417 ± 25

p=0.958

IL-6

90 (80-100)

90 (90-95)

p=0.542

100 (90-100)

90 (90-100)

p=0.511

90 (90-100) 90 (90100)

p=0.774

IL-10

490 (450-550)

470 (445525)

p=0.430

490 (440550)

450 (435520)

p=0.340

470 (430570)

p=0.960

470 (440500)
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Table C-1
Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist
Sun, L., Wang, B.N., Yan, T., Zhang, G.H., & Zheng, H. (2018). Effects of propofol/remifentanil-based total
intravenous anesthesia versus sevoflurane-based inhalational anesthesia on the release of VEGF-C and TGF-β and
prognosis after breast cancer surgery: a prospective, randomized and controlled study. BMC Anesthesiology, 18(1),
N.PAG. https://doi-org.ric.idm.oclc.org/10.1186/s12871-018-0588-3

A. Are the results of the trial valid?

YES

CAN’T

NO

TELL
1. Did the trial address a clearly focused issue?

X

2. Was the assignment of patients to treatments
randomized?
3. Were all of the patients who entered the trial
properly accounted for at its conclusion?
4. Were patients, health workers, and study personnel
“blind” to treatment?
5. Were the groups similar at the start of the trial?

X

6. Aside from the experimental intervention, were the
groups treated equally?
B. What are the results?

X

7. How large was the treatment effect?

8. How precise was the estimate of the treatment
effect?

C. Will the Results Help Locally?

X
X
X

83 female patients undergoing surgery for
breast cancer removal
Significantly higher amounts of VEGF-C
released in Sevoflurane group, minor
difference in recurrence free survival
between groups.
YES

CAN’T
TELL

9. Can the results be applied in your context?

X

10. Were all clinically important outcomes
considered?
11. Are the benefits worth the harms and costs?

X
X

NO
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Table C-2
Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist
Ito, M., Kadoya, T., Funaoka, Y.,Kawai, A., Kim, R., Wakisaka, M.,Y., Ohtani, S., & Okada, M. (2017).
Differences in immune response to anesthetics used for day surgery versus hospitalization surgery for breast
cancer patients. Clinical & Translational Medicine, 6(1), 1–8. Doi: 10.1186/s40169-017-0163-4 https://doiorg.ric.idm.oclc.org/10.1186/s40169-017-0163-4

A. Are the results of the trial valid?

YES

CAN’T

NO

TELL
1. Did the trial address a clearly focused issue?
2. Was the assignment of patients to treatments
randomized?
3. Were all of the patients who entered the trial
properly accounted for at its conclusion?
4. Were patients, health workers, and study
personnel “blind” to treatment?
5. Were the groups similar at the start of the trial?
6. Aside from the experimental intervention, were
the groups treated equally?
B. What are the results?
7. How large was the treatment effect?

8. How precise was the estimate of the treatment
effect?
C. Will the Results Help Locally?

X
X
X
X
X
X

37 female patients undergoing
surgery for breast cancer removal
No difference between the two
groups
YES

CAN’T
TELL

9. Can the results be applied in your context?
10. Were all clinically important outcomes
considered?
11. Are the benefits worth the harms and costs?

X
X
X

NO
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Table C-3
Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist
Buggy, D. J, Burns, D., Ní Eochagáin, A., Riedel, B., & Sessler, D. I. (2018). The effect of anaesthetic technique
during primary breast cancer surgery on neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and return to
intended oncological therapy. Anaesthesia, 73(5), 603–611. https://doi-org.ric.idm.oclc.org/10.1111/anae.14207

A. Are the results of the trial valid?

YES

CAN’T

NO

TELL
1. Did the trial address a clearly focused issue?

X

2. Was the assignment of patients to treatments
randomized?
3. Were all of the patients who entered the trial
properly accounted for at its conclusion?
4. Were patients, health workers, and study personnel
“blind” to treatment?
5. Were the groups similar at the start of the trial?

X

6. Aside from the experimental intervention, were
the groups treated equally?
B. What are the results?

X

7. How large was the treatment effect?

8. How precise was the estimate of the treatment
effect?
C. Will the Results Help Locally?

X
X
X

201 female patients undergoing
surgery for breast cancer removal
Changes in amounts of immune cells
released were similar with propofol
and sevoflurane.
YES

CAN’T
TELL

9. Can the results be applied in your context?

X

10. Were all clinically important outcomes
considered?
11. Are the benefits worth the harms and costs?

X
X

NO
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Table C-4
Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist
Kim, S.H., Lee, J.Y., Lee., S.H., Oh, C.S., Park, H.J., Piao, L., H., Seo, E.H., & Yoon, T.G.
(2018b). Effect of Equipotent Doses of Propofol versus Sevoflurane Anesthesia on Regulatory
T Cells after Breast Cancer Surgery. Anesthesiology, 129(5), 921–931.
https://doiorg.ric.idm.oclc.org/10.1097/ALN.0000000000002382
A. Are the results of the trial valid?
YES
CAN’T
NO
TELL
1. Did the trial address a clearly focused issue?

X

2. Was the assignment of patients to treatments
randomized?
3. Were all of the patients who entered the trial
properly accounted for at its conclusion?
4. Were patients, health workers, and study
personnel “blind” to treatment?
5. Were the groups similar at the start of the trial?

X

6. Aside from the experimental intervention, were
the groups treated equally?
B. What are the results?

X

7. How large was the treatment effect?

8. How precise was the estimate of the treatment
effect?
C. Will the Results Help Locally?

X
X
X

116 female patients undergoing
surgery for breast cancer removal
Propofol-paravertebral TIVA
attenuated the postoperative increase
in the neutrophil-lymphocyte ratio.
YES
CAN’T
NO
TELL

9. Can the results be applied in your context?

X

10. Were all clinically important outcomes
considered?
11. Are the benefits worth the harms and costs?

X
X
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Table C-5
Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist

Kim, S.H., Lee, J. Y., Lee, S.H., Lim, J.A., Oh, C.S., Yoon, T.G., Yang, J. H., & Yoo, Y.B.
(2018a). The effect of propofol and sevoflurane on cancer cell, natural killer cell, and cytotoxic T
lymphocyte function in patients undergoing breast cancer surgery: an in vitro analysis. BMC Cancer,
18, 1. https://doi-org.ric.idm.oclc.org/10.1186/s12885-018-4064-8
A. Are the results of the trial valid?
YES
CAN’T
NO
TELL
1. Did the trial address a clearly focused issue?

X

2. Was the assignment of patients to treatments
randomized?
3. Were all of the patients who entered the trial
properly accounted for at its conclusion?
4. Were patients, health workers, and study personnel
“blind” to treatment?
5. Were the groups similar at the start of the trial?

X

6. Aside from the experimental intervention, were the
groups treated equally?
B. What are the results?

X

7. How large was the treatment effect?

8. How precise was the estimate of the treatment
effect?
C. Will the Results Help Locally?

X
X
X

44 female patients undergoing surgery
for breast cancer removal
No difference in NK cell and CTL
counts between groups.
YES
CAN’T
NO
TELL

9. Can the results be applied in your context?

X

10. Were all clinically important outcomes considered?

X

11. Are the benefits worth the harms and costs?

X
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Appendix D
Cross Study Analysis
AUTHOR / YEAR

COMPARISONS OR
PROTOCOL OF STUDY

OUTCOME/RESULTS

OUTCOME/RESULTS

Study 1
(Sun et al., 2018)

VEGF-C, TGF-b Levels,
Recurrence Free Survival

VEGF-C Levels
Group 1: TIVA
VEGF-C levels increased from 133 to
140 in the preoperative (T0) to
postoperative time (T1). There was a
pre/post changes value of 12 when
comparing the preoperative value to
the postoperative value.
Group 2: Sevoflurane
There was an increase in VEGF-C
levels from 105 to 174 in preoperative
(T0) to postoperative values (T1).
There was a pre-post changes value of
50 when comparing the preoperative
value to postoperative value.
TGF-b
Group 1: TIVA
TGF-b values decreased from 198 to
176 from T0 to T1. There was a
change of 13 when comparing T0 to
T1.
Group 2: Sevoflurane
TGF-b values increased from 197 (T0)
to 211 (T1). There was a change value
of 3 when comparing T0 to T1.

Recurrence Free Survival
Group 1: TIVA
Two patients experienced a
recurrence of their cancer. There
was a recurrence free survival
value of 95% at the two-year
mark in this group.
Group 2: Sevoflurane
Six patients had recurrence of
their cancer in this group. There
was a 78% recurrence free
survival rate in this group.

Group 1: TIVA
T0: Prior to procedure
T1: 24 hours post procedure
T0/T1: Comparison
T3: 2 Year Recurrence Free
Survival
Group 2: Sevoflurane
T0: Prior to procedure
T1: 24 hours post procedure
T0/T1: Comparison
T3: 2 Year Recurrence Free
Survival
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Study 2
(Ito et al., 2017)

Changes in NK Cell activity,
Changes in CD4/8 T Cell Ratio,
Changes in IL-6 Levels
Group 1: Day surgery,
Lidocaine/Propofol/Pethidine
(TIVA)
T0: Preoperative
T1: Postoperative
T2: 24 hours postoperative
Group 2: Hospitalized,
Sevoflurane/Propofol,
systemic-opioid-based
T0: Preoperative
T1: Postoperative
T2: 24 hours postoperative

Changes in NK Cell Activity
Group 1: Day surgery,
Lidocaine/Propofol/Pethidine
(TIVA)
There was a slight decrease in
values from 30.5 ± 9.2
(T0) to 29.0 ± 9.0 (T1). Values
then increased slightly to
32.0 ± 7.5 (T2).
Group 2: Sevoflurane
Values stayed fairly steady through
all time periods, 24.5 ± 13.8 (T0),
31.0 ± 12.3 (T1), and 25.0 ± 9.5
Changes in CD4/8 T Cell Ratio
Group 1: Day surgery,
Lidocaine/Propofol/Pethidine
(TIVA)
The changes in median value of
CD4/8 T Cell ratio increased over
all time periods. The median value
at T0 was 1.31 ± 0.32 which
increased to 1.53 ± 0.64 (T1), and
1.67 ± 0.34 (T2).
Group 2: Sevoflurane
The changes in CD4/8 T Cell
median values decreased from
1.63 ± 0.55 (T0) to 1.23 ± 0.16
(T1), and then returned to close to
baseline 1.61 ± 0.68 at T2.

Changes in IL-6 Levels
Group 1: Day surgery,
Lidocaine/Propofol/Pethidine
(TIVA)
Levels remained fairly
unchanged, 1.1 ± 0.5 (T0) to
1.0 ± 0.65 (T1), between the first
time intervals. There was a sharp
increase in levels at T2 with a
median value of 5.4 ± 1.35.
Group 2: Sevoflurane
There was an increase in median
levels from 2.0 ± 1.94 (T0) to
3.9 ± 2.95 (T1). A larger increase
occurred with a median level of
15.3 ± 7.15 at T2.
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Study 3
(Buggy et al., 2018)

Amount of White Cells,
Neutrophils, Lymphocytes,
Platelets, as well as the
Neutrophil-Lymphocyte Ratio,
Platelet-Lymphocyte Ratio, and
Change in NeutrophilLymphocyte Ratio

White Cell Levels
Group 1: Propofol/Paravertebral
TIVA
There was an increase in white cell
levels from 7.4 (T0) to 9.0 (T1)
Group 2: Sevoflurane/Opioid
There was an increase in white cell
levels from 7.2 (T0) to 9.0 (T1)

Group1:
Propofol/Paravertebral TIVA
T0: Preoperative
T1: 24 hours postoperative

Neutrophils
Group 1: Propofol/Paravertebral
TIVA
There was an increase from 4.7 (T0) to
6.4 (T1).
Group 2: Sevoflurane/Opioid
Levels increased from 4.6 (T0) to 6.5
(T1).

Group 2: Sevoflurane/Opioid
T0: Preoperative
T1: 24 hours postoperative

Lymphocytes
Group 1: Propofol/Paravertebral
TIVA
Levels slightly decreased from 2.0 (T0)
to 1.8 (T1).
Group 2: Sevoflurane/Opioid
There was a slight decrease from 1.9
(T0) to 1.7 (T1).
Platelets
Group 1: Propofol/Paravertebral
TIVA
Levels decreased from 292 (T0) to 268
(T1).
Group 2: Sevoflurane/Opioid
There was a decrease from 265 (T0) to
237 (T1).

Platelet-Lymphocyte Ratio
Group 1: Propofol/Paravertebral
TIVA
There was a slight increase from
142 (T0) to 148 (T1).
Group 2: Sevoflurane/Opioid
The value remained the same for
both time periods 148 (T0) and 148
(T1).
Neutrophil-Lymphocyte Ratio
Group 1: Propofol/Paravertebral
TIVA
The value remained unchanged for
both time intervals with a value of
3.0.
Group 2: Sevoflurane/Opioid
The value remained unchanged at
both time intervals with a value of
4.0
Change in Neutrophil-Lymphocyte
Ratio
Group 1: Propofol/Paravertebral
TIVA
There was a change in the
Neutrophil-Lymphocyte Ratio of
30% for group 1.
Group 2: Sevoflurane/Opioid
There was a change in the
Neutrophil-Lymphocyte Ratio of
81%in group 2.
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Study 4
(Kim et al., 2018b)

Frequency of CD39 Expression,
Frequency of CD73 Expression,
and Median Values of
Neutrophil-Lymphocyte Ratio
Group 1: Propofol (TIVA)
T0: Preoperative
T1:1-hour postoperative
T2: 24 hours postoperative
Group 2: Sevoflurane
T0: Preoperative
T1: 1-hour postoperative
T2: 24 hours postoperative

Frequency of CD39 Expression
Group 1: Propofol (TIVA)
There was a decrease in
expression with values decreasing
from 17.1% (T0), 16.7 ± 7.6%
(T1), to 16.9% (T2).
Group 2: Sevoflurane
There was a decrease in expression
from 17.6% (T0) to 16.5 ± 7.9%
(T1). Expression returned to
baseline of 17.6% at T2.
Frequency of CD73 Expression
Group 1: Propofol (TIVA)
There was a decrease in expression
from 19.4% (T0) to 18.5% (T1).
Expression then increased to
19.2% (T2).
Group 2: Sevoflurane/Opioid
Expression levels remained fairly
steady with expression values of
19.0% (T0), 19.2% (T1) and 19.6%
(T2).

Median Values of NeutrophilLymphocyte Ratio
Group 1: Propofol (TIVA)
Median values remained fairly
unchanged with a value of 1.55
at T0 and 1.62 at T1.
Group 2: Sevoflurane
Median Values decreased from
1.76 at T0 to 1.68 at T1.
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Study 5
(Kim et al., 2018a)

Amount of TNF-a, IL-6, and IL10
Group1: Propofol (TIVA)
T0: Preoperative
T1: 1-hour postoperative
T2: 24 hours postoperative
Group 2: Sevoflurane
T0: Preoperative
T1: 1-hour postoperative
T2: 24 hours postoperative

Amount of IL-6
Group 1: Propofol (TIVA)
The amount increased from 90
(T0) to 100 (T1) and then returned
to baseline of 90 at T2.
Group 2: Sevoflurane
The amount remained unchanged
for all time periods with a value of
90 (T0, T1, and T2).
Amount of IL-10
Group 1: Propofol (TIVA)
The amount remained unchanged
at T0 and T1 with a value of 490,
then decreased to 470 at T2.
Group 2: Sevoflurane/Opioid
The amount decreased from 470
(T0) to 450 (T1) and then returned
to baseline value of 470 at T2.

Amount of TNF-a
Group 1: Propofol (TIVA)
The amount decreased from 410
(T0) to 390 (T1) and then
increased to 420 (T2).
Group 2: Sevoflurane
The amount decreased from
404 ± 42 (T0) to 400 (T1) and
then sharply increased to 417 ±
25 at T2.

